
<table style="text-align:center"><caption><strong>US Market Authorization Counts for Orphan Drugs with Over 5 Market Authorizations</strong></caption>
<tr><td colspan="2" style="border-bottom: 1px solid black"></td></tr><tr><td>Trade Name</td><td>Market Authorizations</td></tr>
<tr><td colspan="2" style="border-bottom: 1px solid black"></td></tr><tr><td>Keytruda</td><td>13</td></tr>
<tr><td>Avastin</td><td>11</td></tr>
<tr><td>Lynparza</td><td>11</td></tr>
<tr><td>Imbruvica</td><td>10</td></tr>
<tr><td>Kalydeco</td><td>10</td></tr>
<tr><td>Opdivo</td><td>10</td></tr>
<tr><td>Gleevec</td><td>9</td></tr>
<tr><td>Revlimid</td><td>9</td></tr>
<tr><td>Adcetris</td><td>7</td></tr>
<tr><td>Darzalex</td><td>7</td></tr>
<tr><td>Humira</td><td>7</td></tr>
<tr><td>Novoseven</td><td>6</td></tr>
<tr><td colspan="2" style="border-bottom: 1px solid black"></td></tr></table>
